Vaxcyte, Inc. (PCVX) announced that enrollment in its two Phase 3 studies—OPUS‑1 and OPUS‑2—has been completed. OPUS‑1 enrolled roughly 4,000 adults and will compare VAX‑31’s safety, tolerability and immunogenicity to the current standard‑of‑care pneumococcal conjugate vaccines, PCV21 and PCV20. OPUS‑2, with about 1,300 participants, will evaluate VAX‑31 when administered concurrently with a seasonal influenza vaccine.
The milestone is significant because VAX‑31 is a 31‑valent pneumococcal conjugate vaccine that offers broader serotype coverage than existing products. The U.S. Food and Drug Administration granted the candidate Breakthrough Therapy designation in May 2025, a status that can accelerate development and review. By completing enrollment, Vaxcyte moves the program closer to the pivotal data needed for a Biologics License Application and potential market entry.
Vaxcyte’s financial position supports continued progress. At the end of 2025 the company held approximately $2.4 billion in cash, cash equivalents and investments, and raised about $600 million in a recent equity offering. The company reported a net loss of $246.5 million for Q4 2025, up from $137.1 million in the same quarter a year earlier, reflecting ongoing investment in research and development and manufacturing scale‑up.
"Completing enrollment in the Phase 3 OPUS‑1 and OPUS‑2 trials represents two important milestones in the development of VAX‑31 and reflects the disciplined execution of our comprehensive clinical program," said Grant Pickering, Chief Executive Officer and Co‑founder. "With VAX‑31, we are aiming to expand the breadth of disease and serotype coverage while ensuring immunogenicity levels remain high to support durable protection." Pickering added that the company’s Phase 1/2 results and carrier‑sparing platform position VAX‑31 as a potential best‑in‑class, next‑generation pneumococcal conjugate vaccine for both adults and children. Andrew Guggenhime, President and Chief Financial Officer, noted that the strong cash position and recent financing give Vaxcyte the resources to execute on its planned clinical, manufacturing and commercial readiness milestones.
Investors have expressed optimism about the enrollment completion, citing the company’s progress toward regulatory submission, the broader serotype coverage of VAX‑31, and the firm’s robust cash reserves. Analysts have highlighted the potential for VAX‑31 to capture market share from existing pneumococcal vaccines and have maintained positive outlooks for the company’s pipeline.
The next steps for Vaxcyte include the analysis of OPUS‑1 data, expected in the fourth quarter of 2026, and the release of OPUS‑2 results in the first half of 2027. Successful outcomes could lead to a Biologics License Application submission and, if approved, a new product that could become the standard of care for adult pneumococcal disease.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.